As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
7 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
7 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
| Jun '23 |
+/-
%
|
||
| Revenue | 258 258 |
5%
5%
|
|
| Gross Profit | 180 180 |
10%
10%
|
|
| EBITDA | 57 57 |
31%
31%
|
|
| EBIT (Operating Income) EBIT | 36 36 |
54%
54%
|
|
| Net Profit | 12 12 |
47%
47%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
| Head office | United States |
| CEO | Michael Graves |
| Employees | 134 |
| Founded | 2007 |
| Website | www.eagleus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


